solian
sanofi-aventis australia pty ltd - amisulpride -
solian 400 mg
sanofi israel ltd - amisulpride - film coated tablets - amisulpride 400 mg - amisulpride - amisulpride - treatment of schizophrenia.
solian 100 mg
sanofi israel ltd - amisulpride - tablets - amisulpride 100 mg - amisulpride - amisulpride - treatment of schizophrenia .
solian
sanofi-aventis new zealand limited - amisulpride 100 mg/ml; - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian 100
sanofi-aventis new zealand limited - amisulpride 100mg; ; ; amisulpride 100mg - tablet - 100 mg - active: amisulpride 100mg excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 100mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian 200
sanofi-aventis new zealand limited - amisulpride 200mg; ; ; amisulpride 200mg - tablet - 200 mg - active: amisulpride 200mg excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 200mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian 400
sanofi-aventis new zealand limited - amisulpride 400mg; ; - tablet - 400 mg - active: amisulpride 400mg excipient: hypromellose lactose monohydrate macrogol stearate 2000 magnesium stearate microcrystalline cellulose powdered cellulose sodium starch glycolate titanium dioxide - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian 200 amisulpride 200 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian 100 amisulpride 100 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian amisulpride 100mg/ml oral solution bottle
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; hydrochloric acid; propyl hydroxybenzoate; purified water; potassium sorbate; saccharin sodium; gluconolactone; sodium gluconate; flavour - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.